Biological markers in DCIS and risk of breast recurrence: A systematic review

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 232-261

  Lari, Sara A ^a   Kuerer, Henry M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biological markers; Breast recurrence; Dcis; Ductal carcinoma in situ

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CELECOXIB; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; HEPARANASE; KI 67 ANTIGEN; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCLEROPROTEIN; STEROID RECEPTOR; SURVIVIN; TAMOXIFEN;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; HUMAN; INTRADUCTAL CARCINOMA; MEDICAL LITERATURE; ONCOGENE C MYC; OVARY TUMOR; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 80053646326     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.232     Document Type: Review

References (74)

1. Kuerer HM. Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. Lancet Oncol 2010;12:2-3.
2. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 2010;102:161-9.
3. Madu CO and Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010;1:150-77.
4. Barker PE. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci 2003;983:142-50.
5. Ludwig JA and Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
6. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
7. Albonico G, Querzoli P, Ferretti S, et al. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev 1998;22:313-8.
8. Hanley K, Wang J, Bourne P, et al. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol 2008;39:386-92.
9. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001;70:303-16.
10. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-44.
11. Lebrecht A, Buchmann J, Hefler L, et al. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast. Anticancer Res 2002;22:1909-11.
12. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2003;79:187-98.
13. Collins LC and Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005;18:615-20.
14. Meijnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008;98:137-42.
15. Altintas S, Lambein K, Huizing MT, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J 2009;15:120-32.
16. Ringberg A, Anagnostaki L, Anderson H, et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001;37:1514-22.
17. DiGiovanna MP, Chu P, Davison TL, et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res 2002;62:6667-73.
18. Kuerer HM, Buzdar AU, Mittendorf EA, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011;117(1):39-47.
19. Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
20. Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005;46:561-8.
21. Kulkarni S, Patil DB, Diaz LK, et al. COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma insitu. BMC Cancer 2008;8:36.
22. Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003;39:622-30.
23. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 2004;30:243-7.
24. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-37.
25. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 2010;10:653.
26. Ma CX, Sanchez CG and Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 2009;23:133-42.
27. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21-9.
28. Eng-Wong J, Costantino JP and Swain SM. The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010;2010:200-3.
29. Chen YY, DeVries S, Anderson J, et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009;9:285.
30. Bundred NJ, Cramer A, Morris J, et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010;16:1605-12.
31. Millar EK, Tran K, Marr P, et al. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence. Pathol Int 2007;57:183-9.
32. Birrell SN, Hall RE and Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neo-plasia 1998;3:95-103.
33. Yu Q, Niu Y, Liu N, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 2010; Epub.
34. de Azambuja E, Cardoso F, de Castro G Jr., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13.
35. Barnes NL, Khavari S, Boland GP, et al. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
36. Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001;85:869-74.
37. Wilson GR, Cramer A, Welman A, et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006;95:1410-4.
38. Chasle J, Delozier T, Denoux Y, et al. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas-a preliminary study. Eur J Cancer 2003;39:1363-9.
39. Zhou CJ, Zhang QH, Zhang TG, et al. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients. Pathol Oncol Res 2009;15:153-8.
40. Guo LL, Gao P, Wu YG, et al. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53. Arch Med Res 2007;38:846-52.
41. Oh YL, Choi JS, Song SY, et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 2001;51:94-9.
42. Jirstrom K, Ringberg A, Ferno M, et al. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer 2003;89:1920-6.
43. de Roos MA, de Bock GH, de Vries J, et al. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 2007;140:109-14.
44. Steeg PS and Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat 1998;52:17-28.
45. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007;12:479-91.
46. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-27.
47. Alkarain A, Jordan R and Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004;9:67-80.
48. Hieken TJ, Farolan M, D'Alessandro S, et al. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. Surgery 2001;130:593-600.
49. Rehman S, Crow J and Revell PA. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 2000;6:256-63.
50. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103:668-75.
51. Chen MK, Yang SF, Lai JC, et al. Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. Clin Chim Acta 2010;411:400-5.
52. Okumura Y, Yamamoto Y, Zhang Z, et al. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer 2008;8:287.
53. Anagnostopoulos GK, Stefanou D, Arkoumani E, et al. Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg 2007;70:285-9.
54. Barnes N, Haywood P, Flint P, et al. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006;94:253-8.
55. Perez EA, Jenkins RB, Dueck AC, et al. C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2011; 29(6):651-9.
56. Maxhimer JB, Pesce CE, Stewart RA, et al. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes. J Am Coll Surg 2005;200:328-35.
57. Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu over-expression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 2002;15:1318-25.
58. Holmes P, Lloyd J, Chervoneva I, et al. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer 2011; Epub.
59. Kepple J, Henry-Tillman RS, Klimberg VS, et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg 2006;192:68-71.
60. Toussaint J, Durbecq V, Altintas S, et al. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One 2010;5: e12100.
61. Witkiewicz AK, Freydin B, Chervoneva I, et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther 2010;10:391-6.
62. Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cy-clooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res 2005;65:1792-9.
63. Tan KB, Yong WP and Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2004;44:24-8.
64. de la Torre J, Sabadell MD, Rojo F, et al. Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome. Eur J Obstet Gynecol Reprod Biol 2010;151:72-6.
65. Bryan BB, Schnitt SJ and Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006;19:617-21.
66. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007;38:197-204.
67. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
68. Roses RE, Paulson EC, Sharma A, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1386-9.
69. Suzuki J, Chen YY, Scott GK, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009;15:3163-71.
70. Yu KD, Wu LM, Liu GY, et al. Different Distribution of Breast Cancer Subtypes in Breast Ductal Carcinoma in situ (DCIS), DCIS with Microinvasion, and DCIS with Invasion Component. Ann Surg Oncol 2010; 18(5):1342-8.
71. Behling KC, Tang A, Freydin B, et al. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Res Treat 2010; Epub.
72. Menter DG, Hoque A, Motiwala N, et al. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol 2001;23:218-28.
73. Hoque A, Sneige N, Sahin AA, et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002;11:587-90.
74. Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J 2010;12:290-5.